Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Announces Conference Call to Report First Quarter of 2012 Financial Results
external link icon
Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
news icon
Repligen Launches the CTech™ SoloVPE® PLUS System
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in complex biological production workflows, from process development scale through cGMP manufacturing.
corporate icon
Viral Vector Manufacturing
Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, retrovirus, exosomes, oncolytic virus, and virus-based vaccines.
external link icon
Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich’s Ataxia Preclinical Development Program
news icon
Repligen acquires FlexBiosys Inc.
Repligen today entered an agreement to acquire FlexBiosys Inc. of Branchburg, NJ. The acquisition is another step in building out Repligen’s Fluid Management franchise, adding a full range of single-use bioprocessing bags and assemblies to our product offering. The addition of FlexBiosys complements and vertically integrates our systems offering, providing a more complete single-use fluid management portfolio of products for our biopharmaceutical manufacturing customers. Welcome FlexBiosys!  
external link icon
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders. "Under Walter's leadership, Repligen has been transformed from a therapeutics company that produced bioprocessing products into a focused bioprocessing industry leader, providing high-value consumable products for biological manufacturers and creating substantial value for our stockholders," commented Karen A. Dawes, Chair of the Board of Repligen. "Walter has been a major force in building this outstanding company, and the Board and I, on behalf of the stockholders, thank Walter for his dedication, vision, and leadership." Ms. Dawes continued, "We are delighted to promote
external link icon
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies and Fc-fusion proteins. Named NGL-Impact ® A Hi pH , the new ligand is the first to address antibody aggregation in low pH elution buffers. While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for “platform” use due to its broad pH operating range.
Ralf Kuriyel, Repligen Senior Vice President R&D, said, “This new best-in-class ligand addresses one of the major pain points in antibody drug purification which is the formation of aggregates during Protein A elution. Our new
external link icon
Repligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program
WALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to treat spinal muscular atrophy (SMA). This first milestone payment was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations by Repligen. Repligen announced the Agreement in January of this year, at which time it received an upfront payment of $5 million. Repligen remains eligible to receive up to $64 million in additional success-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. "Consistent with our strategic decision last August to focus on building Repligen's bioprocessing business while scaling back our investment in therapeutics, we out-licensed the SMA
external link icon
Repligen Reports Second Quarter Fiscal Year 2012 Financial Results Achieves Record Bioprocessing Product Sales